www.chdi-inc.org
CHDI Selects Evotec as Strategic Drug Discovery Partner in the Search for Huntington's Disease Treatments
CHDI Inc., a not-for profit organization pursuing a biotech approach to finding therapies for Huntington's Disease, has chosen Evotec as a strategic partner for helping them advance its drug discovery programs.
Since March 2006, Evotec and CHDI have signed four agreements covering medicinal chemistry, assay development and medium-throughput screening (MTS), ultra-high-throughput screening (uHTS) and library synthesis and management services. These contracts cover most of Evotec's integrated discovery offering. With access to these resources, CHDI has all the tools in place to rapidly discover novel drugs against Huntington's Disease targets and further optimize them to the point of clinical development. Both parties envisage expanding the agreements to accommodate further discovery capabilities of Evotec as and when required.
"As collaborative enablers, CHDI depends on a network of academic and industrial partners to conduct its research efforts. Evotec has an impressive and integrated suite of core competencies that will be critical for our efforts. Looking at Evotec's breadth of skills and expertise in drug discovery coupled with their profound knowledge of CNS diseases we believe we have found the ideal partner in our search for novel treatments that may slow or prevent Huntington Disease."
Dr. Robert Pacifici, Chief Scientific Adviser to CHDI